Remifentanil and Glycemic Response in Cardiac Surgery
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
This study evaluates the effect of using remifentanil during cardiopulmonary bypass surgery
to supress the hyperglycemic response in perioperative period. Half of the participants will
receive continuous intravenous remifentanil during surgery, while the other half will receive
intermittent intravenous fentanyl during surgery. Intermittent intravenous fentanyl
administration is this institution's standard of care.